A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults with Dravet Syndrome (DS)
a study on Dravet Syndrome Seizures Epilepsy
Summary
- Eligibility
- for people ages 2-65 (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
Description
Summary
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Official Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome
Keywords
Dravet Syndrome, Antiseizure medication, Epilepsy, Neurodevelopmental disorders, Developmental and epileptic encephalopathy, LP352, Seizures, DEEp SEA, Bexicaserin, Myoclonic Epilepsies, Syndrome
Eligibility
You can join if…
Open to people ages 2-65
- Diagnosis of DS must fulfill all of the following criteria:
- Participants with seizure onset age >1 and <20 months
- The participant has a history of at least 1 of the following seizure type(s): prolonged generalized tonic-clonic, hemiclonic, myoclonic, tonic, atonic, atypical absence, focal impaired awareness, nonconvulsive status epilepticus
- The participant has a current occurrence of at least 1 of the following countable motor seizure types: generalized tonic-clonic, tonic (bilateral), clonic (bilateral), atonic (bilateral) with truncal/leg involvement, focal motor (including hemiclonic), and focal to bilateral tonic-clonic
- The participant has demonstrated an average of at least 4 countable motor seizures per month for the 3 months prior to Screening.
- The participant has been taking 1 to 4 antiseizure medications (ASMs) at a stable dose for at least 4 weeks prior to Screening.
- The participant, parent, or caregiver is willing and able (in the judgment of the investigator) to comply with completion of the diaries throughout the study.
- The participant must be willing and able to provide written informed consent.
You CAN'T join if...
- The participant has a history of infantile/epileptic spasms.
- The participant has been admitted to a medical facility for treatment of status epilepticus requiring mechanical ventilation within 3 months prior to Screening.
- The participant has a neurodegenerative disorder as indicated by magnetic resonance imaging or genetic testing.
- The participant has an acquired lesion/injury unrelated to the primary etiology that could contribute as a secondary cause of seizures.
- The participant is receiving exclusionary medications.
- The participant has used any cannabis product or cannabidiol that is not in oral solution/capsule/tablet form, not obtained from a government-approved dispensary, or contains ≥50% Delta-9-tetrahydrocannabinol (THC).
- The participant has unstable, clinically significant neurologic (other than the disease being studied, eg, recurrent strokes), psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality which may impact the ability of the participant to participate or potentially confound the study results.
- The participant is unwilling to comply with any of the study requirements or timelines.
Locations
- Site Number - USA18
not yet accepting patients
Los Angeles California 90095 United States - Site Number - USA29
not yet accepting patients
La Jolla California 92037 United States - Site Number - USA26
not yet accepting patients
Los Angeles California 90027 United States - Site Number - USA28
not yet accepting patients
San Francisco California 94904 United States - Site Number - USA24
not yet accepting patients
Palo Alto California 94304 United States - Site Number - USA03
accepting new patients
Tacoma Washington 98405 United States - Site Number - USA25
accepting new patients
Houston Texas 77030 United States
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Longboard Pharmaceuticals
- ID
- NCT06660394
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 160 study participants
- Last Updated